Detailed Information on Publication Record
2005
Damage to ovarian functions in young women treated with ABVD and BEACOPP chemotherapy for Hodgkin lymfoma
ŠMARDOVÁ, Lenka, Zdeněk KRÁL, Martin HUSER and Igor CRHABasic information
Original name
Damage to ovarian functions in young women treated with ABVD and BEACOPP chemotherapy for Hodgkin lymfoma
Name in Czech
Poškození ovariálních funkcí u pacientek léčených režimy ABVD a BEACOPP pro Hodgkinský lymfom
Name (in English)
Damage to ovarian functions in young women treated with ABVD and BEACOPP chemotherapy for Hodgkin lymfoma
Authors
ŠMARDOVÁ, Lenka (203 Czech Republic, guarantor), Zdeněk KRÁL (203 Czech Republic), Martin HUSER (203 Czech Republic) and Igor CRHA (203 Czech Republic)
Edition
Annals of Oncology, 2005
Other information
Language
Czech
Type of outcome
Konferenční abstrakt
Field of Study
30214 Obstetrics and gynaecology
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 4.319
RIV identification code
RIV/00216224:14110/05:00019024
Organization unit
Faculty of Medicine
ISSN
UT WoS
000233670100280
Keywords in English
Hodgkins lymphoma; fertility; ABVD; BEACOPP
Tags
Tags
International impact, Reviewed
Změněno: 22/2/2010 09:33, MUDr. Lenka Šmardová
V originále
Introduction: Depending on the type of the chemotherapy (CT) administered, premature ovarian failure develops in young women, causing clinical symptoms due to the lack of estrogens, and resulting in subsequent sterility. Objectives: Retrospective analysis of the fertility was made in female pts treated with the BEACOPP or ABVD and MOPP(COPP),ABVD CT. Methods: A total of 16 pts underwent the therapy based on the BEACOPP with baseline (n=6) or escal. doses (n=4), or a combination of 4 cycles of the baseline and escal. BEACOPP (n=6). A total of 32 pts were treated with CT in the past, namely using the ABVD (n=25) or the hybrid MOPP(COPP),ABVD alternating regimen (n=7). Results: 5/16 (31 %) of the pts reported oligomenorrhoea or complete amenorrhoea during the BEACOPP. After 6 months from the end of the therapy, half of the pts (n=8) did not menstruate. The menses disappeared during the ABVD or MOPP (COPP)/ABVD in 6/36 (19 %) of the pts. Conclusions: The BEACOPP poses a risk of early menopause and permanent sterility to young patients owing to the presence of several gonadotoxic agents.
In English
Damage to ovarian functions in young women treated with ABVD and BEACOPP chemotherapy for Hodgkin lymfoma.
Links
| NR8469, research and development project |
|